Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Infigratinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 known ✓ | P22607 | 13/20 | 1.00 |
| ▸ | FGFR1 known ✓ | P11362 | 11/20 | 1.00 |
| ▸ | FGFR4 known ✓ | P22455 | 7/20 | 1.00 |
| ▸ | FGFR2 known ✓ | P21802 | 5/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | INSR | P06213 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | ROS1 | P08922 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | BRAF | P15056 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FLT1 | P17948 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Infigratinib SCHEMBL14893408 | 0.97 | FGFR3 (1.00) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL16383021 | 0.96 | FGFR3 (0.92) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL19338005 | 0.95 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL2013451 | 0.95 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL2011033 | 0.95 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL23281490 | 0.95 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL12596389 | 0.95 | FGFR3 (0.91) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL22532488 | 0.92 | FGFR3 (0.85) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL18398033 | 0.92 | FGFR3 (0.85) | FGFR3FGFR1FGFR4FGFR2JAK2 | |
| SCHEMBL2014363 | 0.91 | FGFR1 (0.84) | FGFR3FGFR1FGFR4FGFR2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2751 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260140118-A1 | COMBINATION DRUG | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-21 | — | — | US | claimed |
| WO-2026099481-A1 | METHOD FOR PRODUCING CELLS HAVING AN ACINAR CELL PHENOTYPE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-05-15 | — | — | WO | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4727596-A2 | ANTIBODY-DRUG CONJUGATES AND LINKERS AND METHODS OF USE THEREOF | Ohio State Innovation Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260060936-A1 | INDOLIUM-BASED STABILIZERS OF HYDROPHOBIC DRUGS | TECHNION RES & DEV FOUNDATION (IL) | 2026-03-05 | — | — | US | claimed |
| EP-4701664-A1 | METHODS OF TREATING TKI-RESISTANT AND SDH-DEFICIENT GIST | Guangzhou Healthquest Pharma Co., Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| US-12564559-B2 | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | ORYZON GENOMICS, S.A. (ES) | 2026-03-03 | — | — | US | claimed |
| WO-2014155268-A2 | FGF-R TYROSINE KINASE ACTIVITY INHIBITORS - USE IN DISEASES ASSOCIATED WITH LACK OF OR REDUCED SNF5 ACTIVITY | NOVARTIS AG (CH) | 2014-10-02 | — | — | WO | claimed |
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| WO-2013151913-A1 | TYROSINE KINASE INHIBITOR COMBINATIONS AND THEIR USE | NOVARTIS AG (CH) | 2013-10-10 | — | — | WO | claimed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | claimed |
| WO-2013144339-A1 | FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS | NOVARTIS AG (CH) | 2013-10-03 | — | — | WO | claimed |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2013-09-12 | — | — | US | claimed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | claimed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | claimed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | claimed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | claimed |